Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akebia Therapeutics

2.41
-0.1408-5.52%
Volume:3.42M
Turnover:8.23M
Market Cap:632.74M
PE:-11.62
High:2.56
Open:2.54
Low:2.36
Close:2.55
Loading ...

Akebia Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Stock Track | Akebia Therapeutics Soars 5.28% Pre-market on Stellar Q1 Earnings, Beating Estimates

Stock Track
·
08 May

Akebia Therapeutics Q1 EPS USD 0.03 VS. Ibes Estimate USD -0.04

THOMSON REUTERS
·
08 May

Akebia Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
06 May

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
02 May

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
02 May

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
01 May

Akebia Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
28 Apr

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock

Zacks
·
10 Apr

US High Growth Tech Stocks to Watch in 2023

Simply Wall St.
·
09 Apr

Akebia Therapeutics Price Target Maintained With a $7.50/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment

MT Newswires Live
·
03 Apr

BRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months

Reuters
·
03 Apr

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for Xoanacyl®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

THOMSON REUTERS
·
03 Apr

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

GlobeNewswire
·
03 Apr

Akebia Therapeutics Initiated at Buy by Jefferies

Dow Jones
·
01 Apr